文献速递糖尿病

胰岛素瘤复发背景下的胰岛母细胞增生症:成人低血糖的罕见原因病例报告

A Case Report of Insulinoma Relapse on Background Nesidioblastosis: A Rare Cause of Adult Hypoglycemia.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

本文报告一例63岁白人女性,2013年因高分化胰岛素瘤行远端胰体尾切除术,术后低血糖未缓解,证实为胰腺切缘附近残留胰岛母细胞增生症。尽管使用高剂量二氮嗪及奥曲肽,低血糖发作频率和严重程度仍增加;加用帕瑞肽后传感器监测显示严重低血糖发生。进一步检查发现胰岛素瘤复发,行胰腺次全切除术后随访9个月无低血糖复发。结论提示,当药物治疗无法预防低血糖时,应考虑到胰岛母细胞增生症背景下胰岛素瘤复发的可能。

要点

  • 成人低血糖罕见病因包括胰岛母细胞增生症,术后低血糖未缓解需警惕残留或复发。
  • 高剂量二氮嗪及奥曲肽无效时,加用帕瑞肽可能仍出现严重低血糖。
  • 影像与活检证实胰岛素瘤复发后,胰腺次全切除术可有效控制低血糖。

核心结论

  • 胰岛母细胞增生症背景下胰岛素瘤复发虽罕见,但药物治疗失败时应作为鉴别诊断考虑。

研究设计与样本

  • 单例病例报告:63岁白人女性,2013年因高分化胰岛素瘤行远端胰体尾切除术,术后低血糖未缓解。

主要发现

  • 术后证实胰腺切缘附近残留胰岛母细胞增生症,低血糖发作频率和严重程度增加。
  • 高剂量二氮嗪(225 mg/d)治疗下仍有低血糖,加用奥曲肽因无效停用。
  • 加用帕瑞肽联合二氮嗪75 mg/d期间,皮下传感器监测显示发生严重低血糖。
  • 68Ga-DOTATOC CT/PET、99mTc-纳米胶体闪烁显像及超声内镜细针穿刺活检识别胰岛素瘤复发。
  • 胰腺次全切除术后随访9个月无低血糖复发。

临床怎么用

  • 对胰岛母细胞增生症术后持续低血糖者,应评估残留病变及胰岛素瘤复发。
  • 药物治疗失败时,可考虑进一步影像学及活检明确复发,并评估手术指征。

局限性

  • 单例病例报告,结论外推需谨慎。
  • 帕瑞肽在胰岛母细胞增生症/胰岛素瘤中的免疫表型特征与个体化用药需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Nesidioblastosis is a rare cause of adult hypoglycemia. Current medical therapy can mitigate disease symptoms. However, side effects and limited efficacy may prevent long-term disease management. CASE DESCRIPTION: A 63-year-old white woman presented at our institution on April 2017 with a history of distal spleno-pancreatectomy for well-differentiated insulinoma in 2013. Hypoglycemic events did not resolve after surgery, and residual nesidioblastosis near the pancreatic resection margins was identified. Hypoglycemic episodes increased in frequency and severity despite high-dose diazoxide (DZX) therapy. On April 2016, octreotide was introduced but soon discontinued for inefficacy. When the patient arrived at our attention, add-on pasireotide was started and glucose levels monitored by subcutaneous sensor. Compared with DZX, 225 mg/d alone, sensor glucose during pasireotide + DZX 75 mg/d showed occurrence of severe hypoglycemia. Pasireotide was discontinued, and the instrumental workup (68Ga-DOTATOC CT/positron emission tomography, 99mTc-nanocolloid scintigraphy and echo-endoscopy + fine-needle aspiration biopsy) identified an insulinoma relapse. Subtotal pancreatectomy was performed without further recurrence of hypoglycemia over 9 months of follow-up. CONCLUSIONS: Although insulinoma relapses on background nesidioblastosis rarely occur, they should be considered as an alternate diagnosis when medical therapy fails to prevent hypoglycemia. Further studies are warranted to test whether the immunophenotypic signature of nesidioblastosis/insulinoma may provide insights for a tailored use of pasireotide.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Dauriz M, Maneschi C, Castelli C, et al. A Case Report of Insulinoma Relapse on Background Nesidioblastosis: A Rare Cause of Adult Hypoglycemia. J Clin Endocrinol Metab. 2019. PMID: 30597028. doi:10.1210/jc.2018-02007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。